A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN CO-ADMINISTERED WITH DAPAGLIFLOZIN COMPARED TO SAXAGLIPTIN OR DAPAGLIFLOZIN ALL GIVEN AS ADD-ON THERAPY TO METFORMIN IN SUBJECT WITH TYPE 2 DIABETES: